Joel M Gelfand Highlights Platelet RNA Signature in Psoriasis
Joel M Gelfand, Director Center for Clinical Sciences in Dermatology at University of Pennsylvania School of Medicine, shared a post on LinkedIn:
“An under investigated topic in psoriasis is its impact on platelets. Here, Michael Garshick demonstrates that even when psoriasis is well controlled with biologics platelets remain activated and have a newly discovered RNA signature that predicts future cardiovascular events.
Details here
Álvaro González Cantero has also recently demonstrated that patients with well controlled psoriasis have residual systemic inflammation
Details here
These findings provide more evidence that simply treating the skin may not be enough to lower CV risk and that more holistic multi-pronged approaches are needed. Note, I am a collaborator and author on both papers”
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia